Published • loading... • Updated
Palvella Therapeutics Eyes QTORIN Launch as Rare-Disease Pipeline Expands
Summary by MarketBeat
1 Articles
1 Articles
Palvella Therapeutics Eyes QTORIN Launch as Rare-Disease Pipeline Expands
Palvella Therapeutics (NASDAQ:PVLA) is preparing for a potential commercial launch of QTORIN rapamycin while advancing additional rare skin and vascular anomaly programs, Chief Financial Officer Matt Korenberg said during a Chardan investor session. Korenberg said the company has expanded from deve
·Sioux Falls, United States
Read Full ArticleCoverage Details
Total News Sources1
Leaning Left0Leaning Right0Center1Last UpdatedBias Distribution100% Center
Bias Distribution
- 100% of the sources are Center
100% Center
C 100%
Factuality
To view factuality data please Upgrade to Premium
